Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents.

Trial Profile

Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Torcetrapib/atorvastatin (Primary) ; Atorvastatin
  • Indications Coronary disorders; Myocardial infarction; Stroke; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Mar 2017 Results of retrospective analysis (n=100) published in the American Journal of Cardiology
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top